Search for a trial

Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans

To determine if short-term treatment with the selective beta-2-adrenergic agonist clenbuterol improves glucose disposal via the mTORC2 pathway in lean, healthy male individuals with normal physical activity